The Food and Drug Administration just approved the new type of flu vaccine for adults ages 50 and older. It relies on the ...

Moderna’s newly approved vaccine could allow manufacturers to respond more rapidly to changing influenza strains.

Previously, the COVID-19 immunizations made by Pfizer and Moderna were the only mRNA vaccines on the market.

The FDA approved mFLUSIVA, the first mRNA flu vaccine, for adults 50 and older. Clinical trials showed that mFLUSIVA was approximately 27% more effective than the standard flu shot. The mRNA ...

The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research ...

An mRNA-based flu (influenza) vaccine for adults 50 and over, Moderna’s mFLUSIVA, was approved by the U.S. Food and Drug Administration (FDA) on August 5. The approval offers older adults, who are at ...

What Is mFlusiva, and How Does It Work? The FDA approved mFlusiva to help prevent the flu in adults ages 50 and older. The flu is a viral infection that affects the lungs and breathing airways. It ...

The Food and Drug Administration this week approved the first mRNA flu vaccine for adults 50 and older. Health experts lauded ...

This flu shot, mFlusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab ...

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 ...

A collective wave of excitement swept around the world when Pfizer and BioNTech announced positive early results from their coronavirus vaccine trial last week. Now, biotechnology firm Moderna has ...